Asset Details
Do you wish to reserve the book?
Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience
Do you wish to request the book?
Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Measles, mumps, and rubella virus vaccine (M-M-R(TM)II): A review of 32 years of clinical and postmarketing experience
2012
Overview
Highlights * The 32-year safety profile of M-M-R(TM)II is described using data from postmarketing surveillance. * Of ~575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1x106doses). * This review provides evidence that the vaccine is safe and well-tolerated.
Publisher
Elsevier Limited
Subject
